Quantcast

Latest Mucositis Stories

2011-05-05 00:00:29

Invado Pharmaceuticals announced the completion of a pilot study for NeutraSal® (supersaturated calcium phosphate rinse) in patients experiencing medication-induced xerostomia or dry mouth. NeutraSal® relieved the symptoms of xerostomia in all subjects while also normalizing the pH of the mouth. (PRWEB) May 04, 2011 Invado Pharmaceuticals announced the completion of a pilot study for NeutraSal® (supersaturated calcium phosphate rinse) in patients experiencing medication-induced...

a3d5fcb1aa5698e46744a8142a81e1241
2011-03-24 06:10:00

A NASA technology originally developed for plant growth experiments on space shuttle missions has successfully reduced the painful side effects resulting from chemotherapy and radiation treatment in bone marrow and stem cell transplant patients. In a two-year clinical trial, cancer patients undergoing bone marrow or stem cell transplants were given a far red/near infrared Light Emitting Diode treatment called High Emissivity Aluminiferous Luminescent Substrate, or HEALS, to treat oral...

2011-03-24 00:00:28

Treatment is being developed to reduce oral infection and pain associated with cancer treatments Honolulu, HI and Claremont CA (PRWEB) March 22, 2011 Biotech firm Synedgen announces the award of a competitive Phase II SBIR grant by the National Institutes of Health (NIH) to accelerate the development of Synedgen's proprietary oral disease treatments. Under this 2-year $1.96 M effort, starting on April 1, Synedgen will accelerate the development of RegenasynTM, a topical treatment for oral...

2011-03-23 14:55:00

In the news release, NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002, issued 23-Mar-2011 by NephRx Corporation over PR Newswire, we are advised by the company that the original version should be disregarded. The complete, corrected release follows: NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease --Validates Potential Utility of NX002 as Treatment for this Common and Disabling Condition with Significant Unmet...

2011-03-23 06:30:00

KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ -- NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis. Previously, NephRx reported that NX002 had demonstrated significant efficacy when tested in well-validated animal models of oral mucositis. Mucositis is a debilitating and often dose-limiting condition that affects more than 400,000 cancer patients who receive...

2011-03-01 07:15:00

DALLAS and NEW YORK, March 1, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, will host a conference call on Wednesday, March 23rd to update investors on its ongoing commercial and development strategy. Management will discuss the progress made within each of Access' programs, including an update on...

2011-02-09 07:00:00

DALLAS and NEW YORK, Feb. 9, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, reported it has been receiving positive clinical feedback from doctors and nurse practitioners prescribing MuGard for patients undergoing radiation and chemotherapy for various cancers. For example, Access received feedback...

2010-12-09 07:00:00

DALLAS and NEW YORK, Dec. 9, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has made significant progress in obtaining MuGard reimbursements from various third-party payer networks. Some of the national insurance reimbursements included several state plans from Blue Cross Blue Shield,...

2010-11-11 06:30:00

KALAMAZOO, Mich., Nov. 11, 2010 /PRNewswire/ -- NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients. Separately, NephRx announced...

2010-11-01 13:59:00

DALLAS and NEW YORK, Nov. 1, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has been awarded $1.5 million in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related